Thrombocytosis and Hepatocellular Carcinoma
Purchase on Springer.com
$39.95 / €34.95 / £29.95*
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.
Thrombocytopenia has been reported to be both a risk factor for hepatocellular carcinoma (HCC) development as well as a prognostic factor. Many HCCs also occur in presence of normal platelets.
To examine a cohort of HCC patients with associated thrombocytosis.
Records were examined of a cohort of 634 biopsy-proven and randomly presenting HCC patients without thrombocytopenia.
In the total cohort, 52 patients were identified with thrombocytosis (platelet levels >400 × 109/L) and compared with 582 patients with normal platelet values. The average tumor sizes were 13.1 versus 8.8 cm (p < 0.0001), and their total average bilirubin levels were 0.9 versus 1.5 (p = 0.02), comparing thrombocytosis patients versus normal platelet count HCC patients. These differences were even more pronounced in patients with HCC sizes >5 cm. Thrombocytosis patients were younger and had less cirrhosis, but similar percent with hepatitis B or C or alcohol consumption.
Thrombocytosis in association with HCC occurs in patients with larger tumor sizes and better liver function.
- Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Establishment of world-wide burden of cancer in 2008: GLOBCAN 2008. Int J Cancer. 2010;127:2893–2917. CrossRef
- Kew MC. Epidemiology of chronic hepatitis B virus infection, hepatocellular carcinoma, and hepatitis B virus-induced hepatocellular carcinoma. Pathol Biol (Paris). 2010;58:273–277. CrossRef
- Beasely RP, Hwang LY, Lin CC, Chien CS. Hepatocellular carcinoma and HBV: a prospective study of 22,000 men in Taiwan. Lancet. 1981;22:1129–1133. CrossRef
- Wild CP, Gong YY. Mycotoxins and human disease: a largely ignored global health issue. Carcinogenesis. 2010;31:71–82. CrossRef
- Yu SZ, Chen G. Blue-green algae toxins and liver cancer. China J Cancer Res. 1994;6:9–17. CrossRef
- Zhou TL, Yu SZ. Laboratory study on the relationship between drinking water and hepatoma. Quantitative evaluation using GGT method. Zhonghua Yu Fang Yi Xue Za Zhi. 1990;234:203–205.
- Kew MC. Synergistic interaction between aflatoxin B1 and hepatitis B virus in hepatocarcinogenesis. Liver Int. 2003;23:405–440. CrossRef
- Chang MH, You SL, Chen CJ, et al. Decreased incidence of hepatocellular carcinoma in hepatitis B vaccinees: a 20-year follow-up study. J Natl Cancer Inst. 2009;101:1348–1355. CrossRef
- Lu SN, Wang JH, Liu SL, et al. Thrombocytopenia as a surrogate for cirrhosis and a marker for the identification of patients at high-risk for hepatocellular carcinoma. Cancer. 2006;107:2212–2222. CrossRef
- Kumada T, Toyoda H, Kiriyama S, et al. Incidence of hepatocellular carcinoma in patients with chronic hepatitis B virus infection who have normal alanine aminotransferase values. J Med Virol. 2010;82:539–545. CrossRef
- Lok AS, Seeff LB, Morgan TR, HALT-C Trial Group, et al. Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease. Gastroenterology. 2009;136:138–148. CrossRef
- Carr BI, Guerra V, Pancoska P. Thrombocytopenia in relation to tumor size in patients with hepatocellular carcinoma. Oncology.. 2012;83:339–345. CrossRef
- Carr BI, Guerra V, De Giorgio M, Fagiuoli S, Pancoska P. Small hepatocellular carcinomas and thrombocytopenia. Oncology. 2012;83:331–338. CrossRef
- Nzeako UC, Goodman ZD, Ishak KG. Hepatocellular carcinoma in cirrhotic and noncirrhotic livers. A clinic-histopathologic study of 804 North American patients. Am J Clin Pathol. 1996;105:65–75.
- Okuda K, Nakashima T, Kojiro M, et al. Hepatocellular carcinoma without cirrhosis in Japanese patients. Gastroenterology. 1989;97:140–146.
- Trevisani F, D’Intino PE, Caraceni P, et al. Etiologic factors and clinical presentation of hepatocellular carcinoma. Differences between cirrhotic and noncirrhotic Italian patients. Cancer. 1995;75:2220–2232. CrossRef
- Truant S, Boleslawsky E, Duhamel A, et al. Tumor size of hepatocellular carcinoma in noncirrhotic liver: a controversial predictive factor for outcome after resection. Eur J Surg Oncol. 2012. Epub. 08/03/2012.
- Trousseau A, Bazine V, Cormack J. Lectures on Clinical Medicine. USA: R. Hardwicke; 1867.
- Riess L. Zur pathologischen anatomie des blutes. Arch Anat Physiol Wissensch Med. 1872;39:237–249.
- Levin J, Conley CL. Thrombocytosis associated with malignant disease. Arch Int Med. 1964;114:497–500. CrossRef
- Hwang SJ, Luo JC, Li CP, et al. Thrombocytosis: a paraneoplastic syndrome in patients with hepatocellular carcinoma. World J Gastroenterol. 2004;10:2472–2477.
- Chen CC, Chang JY, Liu KJ, et al. Hepatocellular carcinoma associated with acquired von Willebrand disease and extreme thrombocytosis. Ann Oncol. 2005;16:988–989. CrossRef
- Nickerson HJ, Silberman TL, McDonald TP. Hepatoblastoma, thrombocytosis, and increased thrombopoietin. Cancer. 1980;45:315–317. CrossRef
- Hsiao CC, Chuang JH, Tiao MM, et al. Patterns of hepatoblastoma and hepatocellular carcinoma in children after universal hepatitis B vaccination in Taiwan: a report from a single institution in southern Taiwan. J Pediatr Hematol Oncol. 2009;31:91–96. CrossRef
- Kuo CY, Liu HC, Chang MH, et al. Hepatoblastoma in infancy and childhood: a clinical and pathological study of 32 cases. Zhonghua Min Guo Xiao. 1991;32:79–87.
- Komura E, Matsumura T, Kato T, et al. Thrombopoietin in patients with hepatoblastoma. Stem Cells. 1998;16:329–333. CrossRef
- Stone RL, Nick AM, McNeish IA, et al. Paraneoplastic thrombocytosis in ovarian cancer. N Engl J Med. 2012;366:610–618. CrossRef
- Labelle M, Begum S, Hynes RO. Direct signaling between platelets and cancer cells induces an epithelial-mesenchymal-like transition and promotes metastasis. Cancer Cell. 2011;20:576–590. CrossRef
- Buergy D, Wenz F, Groden C, Brockmann MA. Tumor-platelet interactions in solid tumors. Int J Cancer. 2012;130:2747–2760. CrossRef
- Cho MS, Bottsford-Miller J, Vasquez HG, et al. Platelets increase the proliferation of ovarian cancer cells. Blood. 2012. Epub. 09/10/2012.
- Peterson JE, Zurakowski D, Italiano JE Jr, et al. VEGF, PF4 and PDGF are elevated in platelets of colorectal cancer patients. Angiogenesis. 2012;15:265–273. CrossRef
- Jelkmann W. The role of the liver in the production of thrombopoietin compared with erythropoietin. Eur J Gastroenterol Hepatol. 2001;13:791–801. CrossRef
- Okubo M, Shiota G, Kawasaki H. Thrombopoietin levels in serum and liver tissue in patients with chronic viral hepatitis and hepatocellular carcinoma. Clin Sci (Lond). 2000;99:207–214. CrossRef
- Nalesnik MA, Michalopoulos GK. Growth factor pathways in development and progression of hepatocellular carcinoma. Front Biosci (School Educ). 2012;4:1487–1515. CrossRef
- Yang ZF, Ho DW, Lau CK, et al. Platelet activation during tumor development, the potential role of BDNF–TrkB autocrine loop. Biochem Biophys Res Commun. 2006;346:981–985. CrossRef
- Zhou J, Tang YZ, Fan J, et al. Expression of platelet-derived endothelial cell growth factor and vascular endothelial growth factor in hepatocellular carcinoma and portal vein tumor thrombus. J Cancer Res Clin Oncol. 2000;126:57–61. CrossRef
- Gotzmann J, Fischer AN, Zoler M, et al. A crucial function of PDGF in TGF-beta-mediated cancer progression of hepatocytes. Oncogene. 2006;25:3170–3185. CrossRef
- Stock P, Monga D, Tan X, et al. Platelet-derived growth factor receptor-alpha: a novel therapeutic target in human hepatocellular cancer. Mol Cancer Ther. 2007;6:1932–1941. CrossRef
- Maass T, Thieringer FR, Mann A, et al. Liver specific overexpression of platelet-derived growth factor-B accelerates liver cancer development in chemically induced liver carcinogenesis. Int J Cancer. 2011;128:1259–1268. CrossRef
- Okada H, Honda M, Campbell JS, et al. Acyclic retinoid targets platelet-derived growth factor signaling in the prevention of hepatic fibrosis and hepatocellular carcinoma development. Cancer Res. 2012. Epub. 05/31/2012.
- Campbell JS, Hughes SD, Gilbertson DG, et al. Platelet-derived growth factor C induces liver fibrosis, steatosis and hepatocellular carcinoma. Proc Natl Acad Sci USA. 2005;102:3389–3394. CrossRef
- Soll C, Jang JH, Riener MD, et al. Serotonin promotes tumor growth in human hepatocellular cancer. Hepatology. 2010;51:1244–1254. CrossRef
- Lesurtel M, Clavien P-A. Serotonin: a key molecule in acute and chronic liver injury. Clin Res Hepatol Gastroenterol. 2012. Epub. 06/29/2012.
- Gauglhofer C, Sagmeister S, Schrottmaier W, et al. Up-regulation of the fibroblast growth factor 8 subfamily in human hepatocellular carcinoma for cell survival and neoangiogenesis. Hepatology. 2011;53:854–864. CrossRef
- Miura S, Mitsuhashi N, Shimizu H, et al. Fibroblast growth factor 19 expression correlates with tumor progression and poorer prognosis of hepatocellular carcinoma. BMC Cancer. 2001;12:56. CrossRef
- French DM, Lin BC, Wang M, et al. Targeting FGFR4 inhibits hepatocellular carcinoma in preclinical mouse models. PLoS One. 2012;7:e36713. CrossRef
- Sitia G, Aiolfi R, Di Lucia P, et al. Antiplatelet therapy prevents hepatocellular carcinoma and improves survival in a mouse model of chronic hepatitis B. Proc Natl Acad Sci USA. 2012;109:E2165–E2172. Epub. 07/02/2012.
- Jain S, Harris J, Ware J. Platelets: linking hemostasis and cancer. Arter Thromb Vasc Biol. 2010;30:2362–2367. CrossRef
- Thrombocytosis and Hepatocellular Carcinoma
Digestive Diseases and Sciences
Volume 58, Issue 6 , pp 1790-1796
- Cover Date
- Print ISSN
- Online ISSN
- Springer US
- Additional Links
- Portal vein thrombosis
- Industry Sectors
- Author Affiliations
- 1. Department of Nutritional Carcinogenesis, IRCCS “S. de Bellis”, National Institute for Digestive Diseases, Via Turi 27, 70013, Castellana Grotte, BA, Italy
- 2. Department of Epidemiology, IRCCS “S. de Bellis”, National Institute for Digestive Diseases, Castellana Grotte, Italy